Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States. It is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous systems (CNS) diseases, pain and several types of cancer. The lead compound of the company is ANAVEX 2-73 which is developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. The research and development pipeline of the company includes one clinical drug candidate and several compounds in various stages of the pre-clinical study.